Allogene Therapeutics ALLO
NASDAQ ALLO
$1.33 +0.00 (+0.00%)
At close: Oct 21, 2026 · 4:00 PM EDT

Allogene Therapeutics (ALLO) Receivables (2020)

Updated

Allogene Therapeutics (ALLO) posted Receivables of $3.1 million for Q3 2020, up 287.5% from the prior quarter.

Analysis

Allogene Therapeutics (ALLO) Receivables (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 19.05 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 13.82 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 15.68 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 5.06 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 12.49 Bn
10 Allogene Therapeutics 435.17 Mn -666.72 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 3.10 Mn
Jun 30, 2020 800,000.00
Mar 31, 2020 200,000.00
API Access

Allogene Therapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=ALLO&period=max&api_key=YOUR_API_KEY